Enorama Pharma AB (OSTO:ERMA) Cyclically Adjusted FCF per Share: kr-3.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ERMA Enorama Pharma AB OSTO:ERMA
28 GF Score
Price kr0.33
GF Value kr0.41
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Enorama Pharma AB Cyclically Adjusted FCF per Share?

Enorama Pharma AB OSTO:ERMA 28 Cyclically Adjusted FCF per Share is kr-3.00 as of Mar. 2026. GuruFocus rates OSTO:ERMA with a GF Score™ of 28/100 and a GF Value™ of kr0.41 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Enorama Pharma AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was kr-0.162. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-3.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-26), Enorama Pharma AB's current stock price is kr0.33. Enorama Pharma AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was kr-3.00. Enorama Pharma AB's Cyclically Adjusted Price-to-FCF of today is .


Enorama Pharma AB  (OSTO:ERMA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Enorama Pharma AB Cyclically Adjusted FCF per Share Related Terms


Enorama Pharma AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Enorama Pharma AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enorama Pharma AB Cyclically Adjusted FCF per Share Chart

Enorama Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.87 -2.99

Enorama Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.90 -2.94 -2.95 -2.99 -3.00

OSTO:ERMA vs ZTS, UTHR, VTRS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enorama Pharma AB Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Enorama Pharma AB's Cyclically Adjusted Price-to-FCF falls into.


OSTO:ERMA
28GF Score
Enorama Pharma AB OSTO:ERMA
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enorama Pharma AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enorama Pharma AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.162/133.5600*133.5600
=-0.162

Current CPI (Mar. 2026) = 133.5600.

Enorama Pharma AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.568 101.019 -0.751
201609 -0.681 101.138 -0.899
201612 -0.464 102.022 -0.607
201703 -0.364 102.022 -0.477
201706 -0.686 102.752 -0.892
201709 -0.490 103.279 -0.634
201712 -0.238 103.793 -0.306
201803 -1.097 103.962 -1.409
201806 -0.925 104.875 -1.178
201809 -0.527 105.679 -0.666
201812 -0.639 105.912 -0.806
201903 -1.346 105.886 -1.698
201906 -0.709 106.742 -0.887
201909 -1.206 107.214 -1.502
201912 -1.350 107.766 -1.673
202003 -1.305 106.563 -1.636
202006 -0.302 107.498 -0.375
202009 -0.551 107.635 -0.684
202012 -1.651 108.296 -2.036
202103 -0.314 108.360 -0.387
202106 -0.803 108.928 -0.985
202109 -0.716 110.338 -0.867
202112 -1.063 112.486 -1.262
202203 -0.514 114.825 -0.598
202206 -1.052 118.384 -1.187
202209 -1.105 122.296 -1.207
202212 -0.675 126.365 -0.713
202303 -1.102 127.042 -1.159
202306 -0.061 129.407 -0.063
202309 -0.303 130.224 -0.311
202312 -0.358 131.912 -0.362
202403 -0.235 132.205 -0.237
202406 -0.260 132.716 -0.262
202409 -0.162 132.304 -0.164
202412 -0.055 132.987 -0.055
202503 -0.431 132.825 -0.433
202506 -0.108 133.699 -0.108
202509 -0.161 133.480 -0.161
202512 -0.198 133.390 -0.198
202603 -0.162 133.560 -0.162

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-3.00 mean?
Enorama Pharma AB (OSTO:ERMA) has a Cyclically Adjusted FCF per Share of kr-3.00 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Enorama Pharma AB and its competitors.
Is Enorama Pharma AB's Cyclically Adjusted FCF per Share too high?
Enorama Pharma AB's current Cyclically Adjusted FCF per Share is kr-3.00. Overall, Enorama Pharma AB has a GF Score™ of 28/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enorama Pharma AB's Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Enorama Pharma AB's Cyclically Adjusted FCF per Share of kr-3.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Enorama Pharma AB and its competitors. Enorama Pharma AB's current Cyclically Adjusted FCF per Share is kr-3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enorama Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr0.41, compared to a current price of kr0.33 — trading 19.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is kr-3.00. Enorama Pharma AB's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current Cyclically Adjusted FCF per Share is kr-3.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?

Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued. The current stock price of kr0.33 is trading 19.5% below its estimated GF Value™ of kr0.41. GuruFocus considers Enorama Pharma AB to be Modestly Undervalued.

Key valuation signals for OSTO:ERMA:

  • Cyclically Adjusted FCF per Share: kr-3.00
  • GF Value™: kr0.41 vs. price of kr0.33 (19.5% below fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enorama Pharma AB Business Description

Address Vastra Varvsgatan 19, Malmo, SWE, SE-211 77
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
28GF Score

Get the complete analysis for OSTO:ERMA

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.33
Price
kr0.41
GF Value